Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis
about
CFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisHuman pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling.In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia.Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.Current and future therapies for inherited cholestatic liver diseases.Individualized medicine using intestinal responses to CFTR potentiators and correctors.Cystic fibrosis: a clinical view.Human tissues in a dish: The research and ethical implications of organoid technology.Effects of Pseudomonas aeruginosa on CFTR chloride secretion and the host immune response.Stem cell-derived organoids and their application for medical research and patient treatment.Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators.Stem cell-derived organoids to model gastrointestinal facets of cystic fibrosis.Recent progress in translational cystic fibrosis research using precision medicine strategies.Organoid technology for brain and therapeutics research.Towards a defined ECM and small molecule based monolayer culture system for the expansion of mouse and human intestinal stem cells.Synthetic hydrogels for human intestinal organoid generation and colonic wound repair.Opportunities for organoids as new models of aging.CFTR potentiators: from bench to bedside.Persistent Bacterial Bronchitis: Time to Venture beyond the Umbrella.Using 3D Organoid Cultures to Model Intestinal Physiology and Colorectal Cancer.Imaging organoids: a bright future ahead.Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.Transformative therapies for rare CFTR missense alleles.Intestinal epithelial cell polarity defects in disease: lessons from microvillus inclusion disease.Pancreas 3D Organoids: Current and Future Aspects as a Research Platform for Personalized Medicine in Pancreatic Cancer.Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.Core Concept: Organoids have opened avenues into investigating numerous diseases. But how well do they mimic the real thing?SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretionIon Channel Modulators in Cystic FibrosisIntestinal organoids for modelling intestinal development and diseaseDynamic Formation of Microvillus Inclusions During Enterocyte Differentiation in -Deficient Intestinal OrganoidsGeneration of renewable mouse intestinal epithelial cell monolayers and organoids for functional analysesWhen and how ruling out cystic fibrosis in adult patients with bronchiectasis
P2860
Q28073996-5DD16F4A-ACA0-4C5C-8485-0C47CD70757DQ30313776-4A8411D9-C9F8-4986-A4E3-CBFBD4AA3EF3Q33769791-F203B0A5-7878-4994-B155-84A6C847BF01Q33825789-D77D390C-A971-4F06-B6AF-22B06FEE5B47Q38746661-99F80ABB-617D-4B4B-A927-6E0723279E63Q38754736-0ED29550-E961-4938-8F52-DA3B8FEABAD8Q38962735-241F1354-2A96-4B11-A425-268B418805B4Q38973292-CE6D005B-C8CD-44DF-B4D2-B969E3AB1D7EQ39095721-28DE7D52-C942-4FE3-B032-FCD16B9C992FQ39103385-14FD4123-E874-4043-BF9B-623A23535924Q39229334-7B9430F8-2B57-4311-87ED-8E7A7DBCF15AQ41287880-75907C3E-92DB-443D-8099-C91214132895Q41302801-A8102A27-E0E0-47B5-8494-88CF24B94274Q45872872-E6F5323C-E68A-4567-B982-CA27C530FEAEQ46310313-E4974C2F-66AF-4EE2-8A5F-890A9FD611D2Q47365590-714EE00C-3204-45C3-9D47-55E0514EC614Q47421495-90A5AB38-180B-4FDA-80F4-52ECB0D9AFC2Q47562383-F14CBF1D-646A-4E96-8AB5-78485A0ACBC5Q47599899-4BD46A03-09D0-4C80-AB35-ECB50C2906E9Q47660390-47F03FBB-E58F-4267-BA16-F3AAE39A24C2Q47669248-EAA5A017-54A8-40FF-BC33-26DF806B98A9Q47753249-4001B922-F396-48AA-9EDD-A526341B6611Q48690318-CFAE62C8-1EAC-4FC9-92EB-36B2D5614BB2Q50069400-2C1DC3CC-835A-485E-8B14-96360F12E30EQ52723533-563546F6-EB98-40B1-8F2C-2DB15FC81DAAQ52726462-359AA41F-FA1B-497B-86F7-51493C860694Q53707065-E7858B81-C9ED-4519-BE74-60D8FEB69FC1Q53832776-94A9CE65-25B7-49B0-89B7-F8BE5B678A8FQ56535583-2939A37F-36BF-4E9A-96F7-EF5C66415818Q56966061-7AA432EB-6DAA-44CF-B1B7-11527FF3DD56Q57177121-9886B0B1-0D23-40E0-AD09-435CD18CE7ADQ58565354-255FA733-1D19-40C6-93E4-9C510502ACC5Q58778141-E1B24283-DC23-45E8-8EE3-E81A63072106Q58792962-24A51491-3BA9-4355-B532-D058F74F0FDD
P2860
Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Characterizing responses to CF ...... subjects with cystic fibrosis
@ast
Characterizing responses to CF ...... subjects with cystic fibrosis
@en
Characterizing responses to CF ...... subjects with cystic fibrosis
@nl
type
label
Characterizing responses to CF ...... subjects with cystic fibrosis
@ast
Characterizing responses to CF ...... subjects with cystic fibrosis
@en
Characterizing responses to CF ...... subjects with cystic fibrosis
@nl
prefLabel
Characterizing responses to CF ...... subjects with cystic fibrosis
@ast
Characterizing responses to CF ...... subjects with cystic fibrosis
@en
Characterizing responses to CF ...... subjects with cystic fibrosis
@nl
P2093
P3181
P1476
Characterizing responses to CF ...... subjects with cystic fibrosis
@en
P2093
Annelotte Vonk
Cornelis K van der Ent
Eduard A van de Graaf
Edward E S Nieuwenhuis
Evelien Kruisselbrink
Frank P Vleggaar
Gitte Berkers
Hans Clevers
Harry G M Heijerman
Hettie M Janssens
P2860
P304
P3181
P356
10.1126/SCITRANSLMED.AAD8278
P407
P577
2016-06-01T00:00:00Z